This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Insulet (PODD) Q3 Earnings Preview: How Are Events Shaping Up?
by Zacks Equity Research
Insulet (PODD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Europe Okays Use of Insulet's (PODD) Omnipod With Fiasp
by Zacks Equity Research
Fiasp's operative efficiency coupled with Insulet's (PODD) Omnipod System will provide a new option for both patients and prescribers to support their diabetes management requirements.
What's in Store for AngioDynamics (ANGO) in Q1 Earnings?
by Zacks Equity Research
Expanding product portfolio, international market expansion and cost-saving initiatives to drive AngioDynamics (ANGO) in Q1.
Insulet Advances on Omnipod Reimbursement Update, Runs Risks
by Zacks Equity Research
Insulet (PODD) commences 2018 with favorable reimbursement updates. The company attains several landmarks regarding Omnipod's market reach.
Zacks.com featured highlights include: Entercom, Insulet, ESCO and Tristate
by Zacks Equity Research
Zacks.com featured highlights include: Entercom, Insulet, ESCO and Tristate
4 Top Stocks With the Power of Earnings Acceleration
by Tirthankar Chakraborty
Studies show that a majority of successful stocks see acceleration in earnings before a positive stock price movement.
Insulet (PODD) Q2 Loss Narrower Than Expected, Revenues Lag
by Zacks Equity Research
We are encouraged by the year-over-year improvement in Insulet's (PODD) results on solid uptake of Omnipod system in the United States in Q2.
Insulet (PODD) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Insulet (PODD) delivered earnings and revenue surprises of 76.92% and -6.52%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Hill-Rom (HRC) Q3 Earnings Top Estimates, Margins Expand
by Zacks Equity Research
Hill-Rom (HRC) registers a solid year-over-year revenue rise on strong domestic growth, driven by a robust performance at Patient Support Systems and Surgical Solutions.
Zimmer Biomet (ZBH) Q2 Earnings Top Estimates, Margins Drop
by Zacks Equity Research
The improvement within Zimmer Biomet's (ZBH) global Knee and Hip sales performance and ongoing growth within the Asia Pacific region are encouraging.
GNC Holdings (GNC) Q2 Earnings Beat, Revenues Miss Mark
by Zacks Equity Research
Though GNC Holdings' (GNC) domestic retail comps are slightly weaker than expected, the company performs strongly in e-commerce business and at International segment.
Abiomed (ABMD) Lags Q1 Earnings Estimates, Raises '19 View
by Zacks Equity Research
Abiomed's (ABMD) flagship Impella line continues to drive growth in Q1. A strong guidance instills investors' optimism.
McKesson (MCK) Beats on Q1 Earnings, Reiterates '19 View
by Zacks Equity Research
Strong prospects in Medical-Surgical business drove McKesson's (MCK) Q1. However, the company witnesses solid regulatory hurdles in the McKesson Canada business.
Integra (IART) Reports In-Line Q2 Earnings, Tapers View
by Zacks Equity Research
Integra LifeSciences' (IART) balanced segmental revenue growth in Q2 is encouraging.
Align Technology (ALGN) Beats on Earnings and Revenues in Q2
by Zacks Equity Research
Align Technology (ALGN) gains on solid contributions from Clear Aligner as well as Scanner and Service segments in Q2.
Chemed (CHE) Beats on Q2 Earnings & Revenues, View Raised
by Zacks Equity Research
Chemed (CHE) rides on strong contributions from the Roto-Rooter and VITAS businesses in Q2.
Varian Medical (VAR) Beats Q3 Earnings & Revenue Estimates
by Zacks Equity Research
Varian Medical (VAR) see strong growth in Oncology Systems. Solid guidance boosts investors' optimism.
Thermo Fisher (TMO) Beats on Q2 Earnings, Ups '18 EPS View
by Zacks Equity Research
Thermo Fisher (TMO) is performing well on the back of a series of product launches along with major progress in precision medicine initiatives.
LabCorp (LH) Tops on Q2 Earnings & Revenues, Narrows '18 View
by Zacks Equity Research
LabCorp's (LH) Covance Drug Development business has reported sturdy growth on strategic acquisitions, robust organic growth and a positive foreign currency translation.
Boston Scientific (BSX) Beats on Q2 Earnings, Margins Down
by Zacks Equity Research
Boston Scientific (BSX) registers steady growth across all business lines and geographies in Q2.
Quest Diagnostics (DGX) Q2 Earnings Meet, Guidance Narrowed
by Zacks Equity Research
Quest Diagnostics (DGX) gains on successful execution of its two-point strategy of accelerating growth and driving operational excellence in Q2.
PetMed (PETS) Q1 Earnings Lag Estimates, Reorder Sales Solid
by Zacks Equity Research
We are encouraged by growth in PetMed's (PETS) reorder and new order sales in Q1. Increased online sales buoy optimism.
Insulet Omnipod Insulin Pump Finds Favor in British Columbia
by Zacks Equity Research
Insulet's (PODD) Omnipod has huge market potential in Canada as it is the only tubeless insulin pump sold in the region.
Insulet Starts European Direct Operation, Braces Global Base
by Zacks Equity Research
Insulet's (PODD) goal to begin direct commercial operation in Europe is a year-long endeavor.
Insulet Banks on Omnipod's Growing Market Reach, Runs Risks
by Zacks Equity Research
We are upbeat about the solid uptake of Insulet's (PODD) Omnipod System in the United States and other geographies.